# Study of M4344 in Combination With Niraparib

> **NCT04655183** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **EMD Serono Research & Development Institute, Inc.**

## Conditions studied

- Advanced Solid Tumor
- Breast Cancer

## Interventions

- **DRUG:** Niraparib
- **DRUG:** M4344
- **DRUG:** Niraparib
- **DRUG:** M4344
- **DRUG:** Niraparib
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT04655183
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial withdrawn based on portfolio prioritization; oral ATRi M1774 in combination with niraparib is under investigation in DDRiver Solid Tumor 301
- **Last updated:** 2021-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04655183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04655183, "Study of M4344 in Combination With Niraparib". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04655183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*